Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interview: ‘More Forward Thinking’ Needed For UK IVD Industry As Brexit Looms

Executive Summary

Incoming head of diagnostic regulation at the UK ABHI Steve Lee makes a plea for more detailed MHRA guidance around product registration requirements for the post-EU national market.

You may also be interested in...



‘MDD+’ For The UK, As Future Devices Regulation Will Be A ‘Living Document’

With the UK implementing sovereign device legislation after leaving the EU, there are opportunities for incorporating updated EU and US FDA provisions as regulation evolves.

MHRA’s Lee To Give UK Medtech Industry Greater Diagnostics Focus

The UK ABHI has created a new role for a director of diagnostics regulation, which MHRA IVD’s policy adviser Steve Lee will fill later this month.

Seven Trending Technologies On The Cusp Of Mainstream Uptake

At HIMSS22, NEO.Life’s Jane Metcalfe identified seven trending technologies that are set to move from the fringes of medicine to the center of attention.

Topics

UsernamePublicRestriction

Register

MT143035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel